Natick, MA., June 3, 2022 –(BUSINESS WIRE)– Naveris, Inc. announces the presentation of an abstract related to its flagship diagnostic test for TTMV-HPV DNA (NavDx®) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 3 through June 7, 2022 in Chicago and virtually.
Results of TTMV-HPV DNA testing in the NRG-HN002 phase II clinical trial for patients with p16-positive oropharynx cancer treated with intensity-modulated radiation therapy (IMRT), with or without cisplatin chemotherapy, will be shared in the presentation.
Details of the presentation are as follows:
Title: Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.
Presenter: Sue S. Yom, M.D., Ph.D., Professor and Vice Chair, Strategic Advisory, Department of Radiation Oncology; Professor, Otolaryngology-Head and Neck Surgery, Univ. of California San Francisco (UCSF)
Presentation Session Date/Time: The oral presentation will take place on Friday, June 3, 2022 from 3:45 – 6:45 p.m. EDT, during the session titled “Head and Neck Cancer”
Location: In-Person & Live Stream | S406
Following the presentation, the data presented will be available on the Naveris website at https://www.naveris.com.
About Naveris, Inc.
Naveris’ mission is to improve outcomes for the millions of individuals at risk of developing viral cancers. The company applies its innovative and patented technology to develop molecular diagnostics which enable earlier detection of viral cancers. Naveris’ first commercial-stage diagnostic, NavDx®, is a blood test that supports the clinical management of patients with HPV-driven cancers. Since its launch in 2020, NavDx has become integrated into daily medical practice by over 675 physicians at 250 medical sites, including the majority of the leading Oncology Centers of Excellence in the US. To learn more, visit naveris.com.